new_0222_0417|TALS|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0417|TALS|Long Name|1|1|Talaris Therapeutics Inc Total Current Assets (Quarterly) (USD)|Talaris Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Talaris Therapeutics Inc Inventories (Quarterly) (USD)|Talaris Therapeutics Inc Net PP&E (Quarterly) (USD)|Talaris Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Talaris Therapeutics Inc Total Liabilities (Quarterly) (USD)|Talaris Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Talaris Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Talaris Therapeutics Inc Total Deposits (Quarterly) (USD)|Talaris Therapeutics Inc Book Value (Quarterly) (USD)|Talaris Therapeutics Inc Retained Earnings (Quarterly) (USD)|Talaris Therapeutics Inc Treasury Stock (Quarterly) (USD)|Talaris Therapeutics Inc EV to Revenues|Talaris Therapeutics Inc EV to Earnings|Talaris Therapeutics Inc EV to Free Cash Flow|Talaris Therapeutics Inc EV to Assets (Quarterly)|Talaris Therapeutics Inc PS Ratio|Talaris Therapeutics Inc PE Ratio|Talaris Therapeutics Inc Price to Book Value|Talaris Therapeutics Inc PEG Ratio|Talaris Therapeutics Inc Debt to Equity Ratio|Talaris Therapeutics Inc Dividend Yield|Talaris Therapeutics Inc Shareholder Yield (TTM)|Talaris Therapeutics Inc Percent of Shares Outstanding Short|Talaris Therapeutics Inc Total Receivables (Quarterly) (USD)|Talaris Therapeutics Inc Total Payables (Quarterly) (USD)|Talaris Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Talaris Therapeutics Inc Return on Invested Capital|Talaris Therapeutics Inc Quality Ratio Score|Talaris Therapeutics Inc Momentum Score|Talaris Therapeutics Inc Beta (1Y)|Talaris Therapeutics Inc Sustainable Growth Rate (TTM)|Talaris Therapeutics Inc Institutional Investor Ownership Percentage|Talaris Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Talaris Therapeutics Inc Total Employees (Annual)|Talaris Therapeutics Inc EPS Diluted (Quarterly) (USD)|Talaris Therapeutics Inc SG&A Expense (Quarterly) (USD)|Talaris Therapeutics Inc Shares Outstanding|Talaris Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Talaris Therapeutics Inc Ordinary Shares Number (Quarterly)|Talaris Therapeutics Inc Payout Ratio|Talaris Therapeutics Inc Quick Ratio (Quarterly)|Talaris Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Talaris Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Talaris Therapeutics Inc Effective Tax Rate (TTM)|Talaris Therapeutics Inc Return on Equity|Talaris Therapeutics Inc Net Income (TTM) (USD)|Talaris Therapeutics Inc Revenue (TTM) (USD)|Talaris Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Talaris Therapeutics Inc Revenue (Quarterly) (USD)|Talaris Therapeutics Inc Gross Profit (Quarterly) (USD)|Talaris Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Talaris Therapeutics Inc Net Income (Quarterly) (USD)|Talaris Therapeutics Inc Net Interest Income (Quarterly) (USD)|Talaris Therapeutics Inc Price (USD)|Talaris Therapeutics Inc Total Return Price (USD)|Talaris Therapeutics Inc Enterprise Value (USD)|Talaris Therapeutics Inc 30-Day Average Daily Volume|Talaris Therapeutics Inc 1 Year Price Returns (Daily)|Talaris Therapeutics Inc Short Interest|Talaris Therapeutics Inc PE Ratio (Forward)|Talaris Therapeutics Inc PE Ratio (Forward 1y)|Talaris Therapeutics Inc PS Ratio (Forward)|Talaris Therapeutics Inc PS Ratio (Forward 1y)|Talaris Therapeutics Inc Quarterly EPS Estimates (USD)|Talaris Therapeutics Inc Quarterly Revenue Estimates (USD)|Talaris Therapeutics Inc Quarterly EPS Surprise|Talaris Therapeutics Inc Quarterly Revenue Surprise|Talaris Therapeutics Inc Quarterly Actual EPS (USD)|Talaris Therapeutics Inc Quarterly Actual Revenue (USD)|Talaris Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Talaris Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Talaris Therapeutics Inc Price Target (USD)|Talaris Therapeutics Inc Consensus Recommendation|Talaris Therapeutics Inc Price Target Num Estimates|Talaris Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Talaris Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Talaris Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Talaris Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Talaris Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Talaris Therapeutics Inc Land and Improvements (Quarterly) (USD)|Talaris Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Talaris Therapeutics Inc Other Properties (Quarterly) (USD)|Talaris Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0417|TALS|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0417|TALS||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0417|TALS||5|5|91|91|0|91|0|91|91|91|0|91|91|0|0|0|1.44221105528|0|0|0|1.43827160494|0|0|1.44221105528|0|15.4117647059|90|91|91|0|0|0|0|0|30.625|91.3333333333|183|91.3333333333|91.3333333333|26|0|91|0|0|91.3333333333|91.4|0|0|91|0|0|0|0|91.3333333333|91.3333333333|91.3333333333|1.44221105528|1.44221105528|1.44221105528|1.44117647059|0|15.4117647059|0|0|0|0|91.6666666667|91.6666666667|91.5|0|91.5|91.5|50.8|63|40.6666666667|14.3529411765|40.6666666667|21.4444444444|32.1666666667|91.3333333333|91.3333333333|0|0|0|91|91
new_0222_0417|TALS||6|6|3|3|0|3|0|3|3|3|0|3|3|0|0|0|199|0|0|0|162|0|0|199|0|17|1|3|3|0|0|0|0|0|8|6|1|6|6|7|0|3|0|0|6|5|0|0|3|0|0|0|0|6|6|6|199|199|199|170|0|17|0|0|0|0|3|3|2|0|2|2|5|4|6|17|6|9|6|6|6|0|0|0|3|3
new_0222_0417|TALS||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0417|TALS|202003|202003|202003||||||||||||||||||||||||||||||||||21.1926||-0.2288|1.439||||||-0.2288|||||||||-4.848|-4.848|0.126||||||||||||||||||||||||3.535|0.092|||||
new_0222_0417|TALS|202006|202006|202006||||||||||||||||||||||||||||||||||21.1926||-0.22|1.335||||||-0.22|0||||||||-4.663|-4.663|0.074||||||||||||||||||||||||3.402|0.101|||||
new_0222_0417|TALS|202009|202009|202009||||||||||||||||||||||||||||||||||21.1926||-0.3028|2.182||||||-0.3028|0||||||||-6.417|-6.417|-0.279||||||||||||||||||||||||3.956|0.129|||||
new_0222_0417|TALS|202012|202012|202012|150.751|149.488||2.013||4.773|3.404|1.369||148.005|-43.014||||||||||||||0.374|0.923|0.003|||||||21.1926||-0.3199|2.453|||41.2369|||-0.3199||||-22.707|||||-6.779|-6.779|0.056||||||||||||||||||||||||4.382|0.125||||2.666|0.519
new_0222_0417|TALS|202103|202103|202103|142.803|140.101||2.083||191.366|3.581|187.785||-46.466|-52.313||||||||||||||0.477|0.817|0.001|||||||41.2369|82|-0.2255|2.537|||41.2369|||-0.2255||||-27.158|||||-9.299|-9.299|-0.294|||||||||||-0.2|0|-550||-1.3|0||||||||6.468|0.135||||2.775|0.557
new_0222_0417|TALS|202105|202103|202103|||||||||||||||-21.6477|||||||0||0.0708|||||||||19.1606|||||41.2369|||||||||||||||||16.07|16.07|522.576|||29180||||||||||||||||||||||||
new_0222_0417|TALS|202106|202106|202106|270.47|266.22||2.255||5.461|4.661|0.8||267.353|-63.665||||-10.4298||||2.2292|||0||1.4573||1.265|0.004||||||89.1372|27.3732||-0.41|3.487|40.5711||40.5711|||-0.41|-139.523|||-33.847|||||-11.352|-11.352|-0.295|14.69|14.69|329.7695|201977.3||591241|||||-0.275|0|-49.0909||-0.41|0|0|0|29.25|1.25|4|-1.73|-1.7567|7.57|0.133||||2.928|0.629
new_0222_0417|TALS|202107|202106|202106|||||||||||||||-9.3006||||2.0957|||0||1.6482|||||||||89.6174||||||||||||||||||||||13.81|13.81|294.0669|131764.1667||668694||||||||||||||1.25||-1.73||||||||
new_0222_0417|TALS|202108|202106|202106|||||||||||||||-6.7622||||1.7955|||0||1.9637|||||||||87.9396|||||41.3459|||||||||||||||||11.61|11.61|213.8059|42412.3333||811904|||||||||||0|0|29.25|1.25|4|-1.645|-1.895|||||||
new_0222_0417|TALS|202109|202109|202109|258.227|254.734||2.994||5.676|4.982|0.694||255.649|-76.606||||-7.9703||||2.1595|||0||2.0149||1.182|0.004||||||68.0695|40.6694|107|-0.32|3.874|40.7127||40.7127|||-0.32|0|||-40.371|||||-12.941|-12.941|0.116|13.56|13.56|297.3302|41197||820314|||||-0.275|0|-16.3636||-0.32|0||||||||9.183|0.167||||3.404|1.146
new_0222_0417|TALS|202110|202109|202109|||||||||||||||-11.6044||||2.6898|||0||1.9801|||||||||68.1581||||||||||||||||||||||16.89|16.89|432.9035|39228.3333||806140||||||||||||||1.25||||||||||
new_0222_0417|TALS|202111|202109|202109|||||||||||||||-7.5384||||2.0965|||0||2.4664|||||||||66.9805|||||41.3546|||||||||||||||||12.96|12.96|281.2216|64778.2667||1019979|||||||||||||29.5|1.25|4|-1.585|-1.7267|||||||
new_0222_0417|TALS|202112|202112|202112|||||||||||||||-10.1214||||2.4734|||0||3.4562|||||||||70.5765||||||||||||||||||||||15.29|15.29|377.5778|162452.0667||1429301|||||-0.35|0|||||0|||1.25||-1.6433|-1.65|||||||
new_0222_0417|TALS|202201|202112|202112|||||||||||||||-3.6252||||1.5254|||0||2.7334|||||||||65.9849||||||||||||||||||||||9.43|9.43|135.2399|125318.0333||1130370|||||||||||||25.75|1.25|4|||||||||
new_0222_0417|TALS|202202|202112|202112|||||||||||||||-2.162||||1.3119|||0|||||||||||||||||||||||||||||||||8.11|8.11|80.6518|53669.2667|||||||||||||0|0||||||||||||